AEON

AEON Biopharma, Inc. Class A · AMEX

Sector Health Technology
Industry Pharmaceuticals: Major
Website aeonbiopharma.com
Employees(FY) 8
ISIN US00791X1000

Performance

-7.83%

1W

-77.79%

1M

-84.53%

3M

-67.52%

6M

-78.75%

YTD

-85.19%

1Y

Profile

AEON Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on developing botulinum toxins. It develops ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, which completed a Phase 2 study for the treatment of cervical dystonia and has an ongoing Phase 2 study for the treatment of both chronic and episodic migraine. AEON Biopharma, Inc. is based in Irvine, California.

Advanced Technical Analysis

Technical Analysis of AEON 2024-05-10

Overview:

In analyzing the technical indicators for AEON stock over the last 5 days, we will delve into the trends, momentum, volatility, and volume indicators to provide a comprehensive outlook on the possible stock price movement in the coming days. By examining key metrics such as moving averages, MACD, RSI, Bollinger Bands, and OBV, we aim t...

See more ...

Recent News & Updates

2024-05-14 04:05
AEON Biopharma Reports First Quarter 2024 Financial Results(Globenewswire)
2024-05-08 21:35
AEON Biopharma, Inc. (AEON) Loses -79.2% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner(Yahoo Finance)
2024-05-08 20:00
AEON Biopharma Provides Update on Development Pipeline(Globenewswire)
2024-05-03 04:08
US Equity Markets Close Higher Friday Following Weak Jobs Report(Yahoo Finance)
2024-05-03 03:55
Sector Update: Health Care Stocks Mixed Late Afternoon(Yahoo Finance)
2024-05-03 02:37
Top Midday Decliners(Yahoo Finance)
2024-05-02 21:05
Sector Update: Health Care Stocks Mixed Pre-Bell Friday(Yahoo Finance)
2024-05-02 20:31
AEON Biopharma Shares Slump Pre-Bell After Failed Chronic Migraine Phase 2 Trial(Yahoo Finance)
2024-05-02 19:00
AEON Biopharma Announces Preliminary Top-Line Results from Phase 2 Interim Analysis of ABP-450 in the Preventive Treatment of Chronic Migraine(Globenewswire)
2024-03-30 10:53
CORRECTION -- AEON Biopharma Announces Redemption of Public Warrants(Globenewswire)
2024-03-29 04:15
AEON Biopharma Announces Redemption of Public Warrants(Globenewswire)
2024-03-29 03:45
AEON Biopharma Reports Fourth Quarter and Full Year 2023 Financial Results(Globenewswire)
2024-03-19 16:30
AEON Biopharma Announces Clinical Update and Productive End-of-Phase 2 Meeting with FDA on ABP-450 (prabotulinumtoxinA) for the Preventive Treatment of Migraine(GlobeNewswire)
2024-03-19 16:29
AEON Biopharma Announces $15 Million Financing Transaction and Termination of Forward Purchase Agreements(GlobeNewswire)
2024-03-19 04:30
AEON Biopharma Announces Clinical Update and Productive End-of-Phase 2 Meeting with FDA on ABP-450 (prabotulinumtoxinA) for the Preventive Treatment of Migraine(Globenewswire)
2024-01-18 16:05
AEON Biopharma Presents Positive Clinical and Pre-clinical Data for ABP-450 (prabotulinumtoxinA) in Treating Cervical Dystonia and PTSD, Respectively, at a Leading Neurotoxin Conference(GlobeNewswire)
2024-01-18 03:05
AEON Biopharma Presents Positive Clinical and Pre-clinical Data for ABP-450 (prabotulinumtoxinA) in Treating Cervical Dystonia and PTSD, Respectively, at a Leading Neurotoxin Conference(Globenewswire)
2023-12-12 08:00
AEON Biopharma Completes Enrollment in Phase 2 Study of ABP-450 (prabotulinumtoxinA) for Preventive Treatment of Chronic Migraine(GlobeNewswire)
2023-12-11 19:00
AEON Biopharma Completes Enrollment in Phase 2 Study of ABP-450 (prabotulinumtoxinA) for Preventive Treatment of Chronic Migraine(Globenewswire)
2023-11-14 15:49
AEON Biopharma Inc Reports Q3 2023 Financial Results Amid Clinical Advancements(Yahoo Finance)
2023-11-12 19:15
AEON Biopharma Reports Third Quarter 2023 Financial Results(Globenewswire)
2023-10-19 04:05
AEON Biopharma Announces Topline Results from Phase 2 Trial of ABP-450 (prabotulinumtoxinA) for the Preventive Treatment of Episodic Migraine(Globenewswire)
2023-08-28 20:00
AEON Biopharma Presents Positive Results from Phase 2 Clinical Trial of ABP-450 (prabotulinumtoxinA) in Cervical Dystonia at the International Parkinson and Movement Disorders Society Congress®(Yahoo Finance)
2023-08-23 20:00
AEON Biopharma Receives Notice of Allowance from USPTO for a Patent Covering Use of Botulinum Toxins to Treat Migraine Headache(Yahoo Finance)
2023-08-15 19:00
Strathspey Crown Holdings Group, LLC Provides Clarifying Statement Regarding Form 4 Filing with SEC for Holdings in AEON Biopharma(Yahoo Finance)
2023-07-23 19:00
AEON Biopharma Announces Closing of Business Combination with Priveterra Acquisition Corp. and Provides Pipeline Update(Yahoo Finance)

Page 1 of 1

previousnext